The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis

Huddam B., Basaran M., Kocak G., Azak A., Yalcin F., Reyhan N. H., ...Daha Fazla

INTERNATIONAL UROLOGY AND NEPHROLOGY, cilt.47, sa.8, ss.1423-1428, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s11255-015-1015-z
  • Dergi Adı: INTERNATIONAL UROLOGY AND NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1423-1428
  • Çanakkale Onsekiz Mart Üniversitesi Adresli: Evet

Özet

Encapsulated peritoneal sclerosis (EPS) is a rare complication of long-term peritoneal dialysis usually associated with the inadequacy and early termination of dialysis modality. Adequate treatment of peritoneal fibrosis has not been achieved by medical intervention so far. Mycophenolate mofetil (MMF), which inhibits inosine monophosphate dehydrogenase reversibly and highly selectively, is the most widely used drug for maintenance immunosupression in renal transplantation. Recent studies have shown that MMF has also antifibrotic effects. In this study, we evaluated the effects of MMF on EPS model in rats based on antifibrotic effects.